
PUBLISHED IN **Visionary Vogues** · Magazine column · web
PUBLISHED 13 November 2026
AUTHOR Ravi R. Iyer, MD
SOURCE https://visionaryvogues.com/the-great-american-healthcare-illusion-ravi-iyer
RECORDED 23 November 2026 · record AR-2026-11-002

THE HEALTHCARE RECKONING · PART 1 OF 4

The Great American Healthcare Illusion

When insurance became the product, and health became the afterthought.

By **Ravi R. Iyer, MD**



Key art as published by Visionary Vogues. Retained as part of the record of how the piece appeared.

- An exposé of the economic contradictions, institutional
- incentives, and fundamental misconceptions that have
- transformed American healthcare into one of the most
- expensive and least transparent purchasing systems in the
- modern economy.

THE MOST EXPENSIVE PURCHASE NOBODY UNDERSTANDS

Imagine walking into a boardroom and presenting the following business proposal.

- Your company will commit millions of dollars annually to
- purchasing a service.

You will not know the true cost of what you are purchasing.

- You will not know how much of your payment reaches the
- people actually delivering the service.

You will not know how much is retained by intermediaries.

You will have limited ability to compare competing suppliers on price, quality, or measurable outcomes.

And perhaps most astonishingly, the people responsible for managing this expenditure may be compensated through arrangements that are not always aligned with minimizing your costs.

- Would any competent board of directors approve such an
- arrangement?
- Would any chief financial officer tolerate it?
- Would any chief executive describe it as sound corporate
- governance?

Yet this is remarkably close to how much of employer-sponsored healthcare operates in America.

Corporations that negotiate relentlessly over raw materials, software licenses, logistics contracts, real estate, and professional services routinely surrender substantial control over one of their largest expenditures.

Healthcare.

- And they do so within a system that has managed to transform
- an extraordinary collection of medical capabilities into an
- extraordinarily confusing commercial enterprise.

The question is no longer simply why healthcare costs so much.

- The more disturbing question is:
- How did the people paying for healthcare become so
- disconnected from the economics of what they purchase?
- And perhaps more importantly:
- How did we create a system in which financing healthcare
- became more important than producing health?

I. THE FIRST ILLUSION: THAT HEALTHCARE IS A FREE MARKET

- We have spent decades discussing American healthcare as
- though it were simply another marketplace.
- Supply and demand.

- Competition.
- Consumer choice.
- Price discovery.
- Market efficiency.
- These are powerful economic concepts. They have produced
- extraordinary prosperity when applied to markets in which
- buyers and sellers possess meaningful freedom to transact.

But healthcare introduces a variable that changes the entire equation.

Fear.

More precisely, the fear of pain, disability, disease, and death.

Consider two transactions.

A consumer enters an automobile showroom. The salesperson offers a vehicle for $60,000.

The consumer can negotiate, compare alternatives, postpone the purchase, or walk away.

Now consider a father standing in an emergency department while his child struggles to breathe.

What is the price of oxygen?

- What is the price of the emergency physician?
- What is the price of the medication that might save the child's
- life?
- What is the price of another hour of life?

The father is not negotiating.

- He is pleading for rescue.
- The economic relationship has fundamentally changed.
- In conventional markets, the buyer possesses the power to
- refuse.

In an acute medical crisis, refusal may mean death.

A market in which the buyer cannot meaningfully walk away is not functioning like an ordinary free market.

- It is a market characterized by profound asymmetry of
- information, urgency, emotional vulnerability, and unequal
- negotiating power.

This does not mean that competition has no place in healthcare.

- Routine laboratory testing, elective imaging, generic
- pharmaceuticals, scheduled procedures, and many preventive
- services can be subjected to meaningful price comparison.
- But the fundamental error is to assume that the same
- commercial rules can govern an emergency resuscitation and a
- routine blood test.

They cannot.

And when we pretend otherwise, we create an economic fiction that disguises the coercive realities of medical necessity.

II. THE SECOND ILLUSION: THAT INSURANCE IS HEALTHCARE

Insurance is a remarkable financial invention.

- It allows individuals to pool risks that would otherwise be
- financially devastating.

A homeowner does not expect an insurance policy to pay for every lightbulb, plumbing repair, or coat of paint.

The policy exists primarily to protect against catastrophic loss.

> The house burns down.
> The roof collapses.
> A flood destroys the property.

Insurance transfers the financial consequences of extraordinary risk across a larger population.

But American health insurance has evolved into something quite different.

It is increasingly expected to finance not merely catastrophe but the cost of much of ordinary existence.

- Office visits.
- Laboratory tests.
- Prescription drugs.
- Routine diagnostics.
- Preventive services.
- Chronic disease management.
- And the administrative infrastructure necessary to process,
- authorize, adjudicate, contest, and reimburse all these
- transactions.
- Some of this evolution has sound clinical justification. Preventive
- services and essential chronic disease treatments can avert
- expensive complications, and financial barriers can deter
- appropriate care.

The problem is not that insurance pays for prevention.

- The problem is that we have confused the financial mechanism
- used to pay for healthcare with the healthcare itself.
- An insurance policy does not lower blood pressure.

> A claims administrator does not reverse atherosclerosis.
> A prior authorization does not restore kidney function.

A pharmacy benefit manager does not, by virtue of managing a benefit, make a patient healthier.

- These institutions may perform necessary financing,
- coordination, and safety functions.

> But they are not the biological intervention.
> They are the architecture surrounding it.

And the architecture has become so elaborate that the act of financing healthcare can consume enormous resources before a single therapeutic benefit reaches the patient.

We have created an industry around paying for medicine.

Then we have increasingly treated that industry as though it were medicine.

- Insurance became the product. Health became the
- afterthought.

III. THE THIRD ILLUSION: THAT PRICE REFLECTS VALUE

In a functioning competitive market, prices convey information.

They tell buyers something about scarcity, production costs, demand, and competing alternatives.

- But what does a hospital charge of $10,000 actually tell us?
- Does it mean the service costs $10,000 to provide?
- Does it mean the hospital receives $10,000?
- Does it mean the insurer pays $10,000?
- Does it mean another insurer pays $6,000?
- Does it mean an uninsured patient is presented with an entirely
- different amount?
- Does it mean the patient receives care worth $10,000?

Not necessarily.

American healthcare frequently operates with several different prices for the same service.

- The chargemaster price.
- The negotiated commercial insurance price.
- The Medicare payment.
- The Medicaid payment.
- The cash price.

The patient's deductible and coinsurance obligation.

And sometimes additional fees for facilities, physicians, supplies, or ancillary services.

- These differences can arise from legitimate variations in
- contracts, services, and patient circumstances.
- But the resulting opacity makes ordinary price discovery
- extraordinarily difficult.

The employer sees a premium or claims expenditure.

The employee sees a deductible, copayment, or explanation of benefits.

> The provider sees a reimbursement schedule.
> The insurer sees contractual rates.
> The intermediary sees its own compensation arrangements.
> Who sees the entire transaction?

Often, no single participant sees all its economic dimensions.

And this fragmentation creates fertile ground for inefficiency.

- When buyers cannot reliably compare prices, competition
- weakens.
- When compensation structures are opaque, accountability
- weakens.
- When the price of an intervention is disconnected from its
- clinical value, rational purchasing becomes difficult.

A $500 test that prevents a $50,000 complication may represent exceptional value.

- A $5,000 intervention that produces no meaningful clinical
- benefit may represent waste.

But without transparent prices and meaningful outcomes, how does the purchaser distinguish between the two?

The problem is not merely that healthcare is expensive.

It is that healthcare purchasing often lacks the information necessary to determine whether expensive means valuable.

IV. THE FOURTH ILLUSION: THAT THE EMPLOYER IS THE CUSTOMER

Consider the employer-sponsored healthcare system.

The employer finances the benefit, directly or through insurance premiums.

> The employee receives the care.
> The physician recommends or provides the service.
> The hospital or pharmacy delivers it.

The insurer or third-party administrator processes the claim.

A pharmacy benefit manager may negotiate drug arrangements and manage pharmacy benefits.

Multiple parties participate in the transaction.

- But who is the customer?
- The employer?
- The patient?
- The insurer?
- The government?
- The answer changes depending on which relationship we
- examine.

- And therein lies a fundamental problem of economic
- accountability.
- The person receiving the care is often not the person
- negotiating the price.

The organization financing the care is often not the organization determining medical necessity.

- The entity negotiating a pharmaceutical contract may be
- compensated through arrangements that are not fully visible to
- the employer.

The physician responsible for clinical judgment may have little knowledge of the patient's actual financial exposure.

And the employee may be asked to make decisions without understanding the economic or clinical alternatives.

This is not a simple buyer-seller relationship.

It is a fragmented network of principals, agents, intermediaries, and competing incentives.

In economics, this creates what is known as a principal-agent problem.

One party delegates decisions to another party whose incentives may not be perfectly aligned with its own.

- Now multiply that problem across thousands of employers,
- insurers, hospitals, pharmaceutical companies, pharmacy
- benefit managers, and healthcare providers.

> The resulting complexity is not incidental.
> It is structural.
> And complexity has a commercial consequence.

When nobody fully owns the purchasing decision, nobody is fully accountable for the purchasing result.

V. THE FIFTH ILLUSION: THAT MORE MEDICAL SPENDING NECESSARILY PRODUCES MORE HEALTH

America possesses some of the most extraordinary medical capabilities in human history.

- Advanced imaging.
- Robotic surgery.
- Molecular diagnostics.
- Genetic testing.
- Targeted therapies.
- Biological medicines.
- Organ transplantation.
- Precision oncology.
- Artificial intelligence.

- Yet medical sophistication and population health are not
- synonymous.
- The United States spends substantially more per person on
- healthcare than other wealthy nations, without consistently
- achieving superior population-level outcomes.
- The causes are complex.
- Prices matter.
- Administrative costs matter.
- Chronic disease burden matters.
- Social conditions matter.
- Access matters.
- Clinical practice patterns matter.
- But there is another distinction worth examining.

We have become exceptionally sophisticated at financing episodes of medical intervention while remaining comparatively unsophisticated at financing the trajectory of human health.

> Consider a hypothetical 45-year-old executive.
> He has gradually increasing visceral adiposity.

- His blood pressure is rising.
- His insulin sensitivity is declining.
- His sleep is deteriorating.
- His inflammatory biomarkers may be worsening.
- His cardiovascular risk is accumulating.

None of these developments necessarily produces an immediate medical catastrophe.

> Indeed, he may feel perfectly well.
> He continues working.
> His employer continues paying health insurance premiums.

His annual medical utilization may remain relatively modest.

Then, at 57, he suffers a myocardial infarction.

- Suddenly the system mobilizes.
- Emergency transportation.
- Cardiac catheterization.
- Coronary intervention.
- Hospitalization.
- Medication.
- Rehabilitation.

Follow-up.

- The machinery of healthcare financing activates around a
- recognized medical event.

The intervention may be lifesaving and entirely appropriate.

But consider the question that preceded the catastrophe.

What if we had understood his risk trajectory twelve years earlier? What if appropriate prevention had reduced his probability of experiencing that event? What if his employer had viewed the maintenance of his health with the same seriousness it applies to maintaining a critical industrial asset?

- Not every heart attack is preventable. Not every biomarker is
- clinically actionable. And more testing is not automatically
- better medicine.
- But many major cardiovascular risk factors are identifiable and
- modifiable long before a catastrophic event.
- The distinction is profound.
- We have built an elaborate financial system around the
- catastrophe of the moment, while underinvesting in the
- intelligent management of the trajectory of a life.

VI. THE BIOLOGICAL PARADOX: THERE IS NO SEPARATE THING CALLED

DISEASE

- As a physician-scientist, I find another misconception
- particularly revealing.

We commonly speak of health and disease as though they were two separate states of existence.

As though health were life functioning normally, and disease were some alien force invading the organism.

> But biology is more subtle.
> There is only life.

- Life operating according to the laws of physics, chemistry,
- physiology, adaptation, and time.

The same biological systems that sustain function can, under different conditions, produce dysfunction.

Inflammation can protect against infection.

Persistent dysregulated inflammation can contribute to tissue damage.

> Cellular proliferation enables healing.
> Uncontrolled proliferation can become malignancy.
> Coagulation prevents fatal hemorrhage.

Inappropriate thrombosis can produce a stroke or myocardial infarction.

The mechanisms are not inherently separate.

Their context, regulation, timing, and consequences determine whether they sustain function or contribute to its breakdown.

- Disease is a clinically useful description of patterns of
- dysfunction.

But it is not a second form of life.

- Health and disease are both expressions of life operating
- through biological rules, sometimes in functional alignment,
- sometimes in destructive dysregulation.

And life continues its inexorable progression toward its eventual end.

- The purpose of medicine, therefore, cannot be the permanent
- abolition of biological risk.
- That is impossible.
- Its purpose is to understand those risks, preserve function,
- reduce avoidable suffering, and expand the possibilities available
- to the individual during the time that remains.

This distinction should transform how we define healthcare value.

A procedure is not valuable merely because it was performed.

> A test is not valuable merely because it produced data.
> A drug is not valuable merely because it changed a number.

The ultimate measure of healthcare is whether it meaningfully improves the experience, function, longevity, or possibilities of human life.

VII. WHAT ARE PATIENTS REALLY BUYING?

> Imagine a patient receiving a diagnosis of cancer.
> The immediate experience is not an economic calculation.
> It is fear.

- What does this mean?
- Will I survive?
- Will I suffer?
- What happens to my family?
- Can I continue working?
- What are my options?
- How certain is the diagnosis?
- What is the probability of success?
- What happens next?

The physician's task is not simply to prescribe treatment.

It is to transform uncertainty into an intelligible landscape of possibilities.

> To distinguish what is known from what is suspected.

> To explain what can be controlled and what cannot.
> To provide a credible path forward.

- And to accompany the patient through decisions whose
- consequences may be profound.

This is why the real service being purchased in healthcare is more fundamental than the procedure or prescription.

Patients are purchasing the best achievable combination of restored function, relief from suffering, reduction of fear, and informed confidence in the face of uncertainty.

> Not absolute certainty.
> Medicine cannot honestly promise that.

But it can offer understanding, judgment, competence, and the disciplined pursuit of better outcomes.

This is the essence of the physician's covenant.

- And it is profoundly different from the logic of an insurance
- claim.

VIII. THE BOARDROOM'S MOST EXPENSIVE BLIND SPOT

Now return to the employer.

A chief executive understands that the enterprise depends on the performance of its people. A chief financial officer understands the importance of capital allocation. A chief operating officer understands the cost of inefficiency. A chief risk officer understands the consequences of unmanaged exposure.

Yet the healthcare purchasing system frequently separates all four of these disciplines.

- The CFO sees premiums and claims.
- The HR department sees benefits and employee satisfaction.
- The insurer sees utilization.
- The provider sees clinical encounters.
- The employee experiences health or illness.

> Each sees a fragment.
> Few see the entire picture.
> And the fragmentation produces a strategic blind spot.

What would happen if employers began asking a different set of questions?

- Not simply:
- How much will our insurance premium increase next year?

But:

What are we actually paying for each pharmaceutical? What are the true net prices after rebates and administrative compensation? Which hospitals deliver better outcomes for comparable patients? Which diagnostic services can be purchased at transparent prices? Which interventions reduce avoidable complications? Which expenditures improve employee health, rather than

merely increasing medical utilization? And which intermediaries genuinely add value commensurate with their compensation?

> These are not radical questions.
> They are the ordinary questions of responsible purchasing.

Yet in American healthcare, asking them can seem revolutionary.

IX. THE ECONOMICS OF BLINDNESS

- Let us consider a hypothetical corporation with 10,000
- employees.

Suppose its total employer healthcare expenditure averages $15,000 per employee annually.

- That represents:
- ILLUSTRATIVE EMPLOYER HEALTHCARE EXPENDITURE
- Covered employees
- 10,000
- Annual cost per employee
- $15,000
- Total annual employer expenditure
- $150 million
- Potential savings under alternative scenarios
- 5% savings
- $7.5 million
- 10% savings
- $15 million
- 15% savings
- $22.5 million

Hypothetical illustration, not an estimate of achievable savings. Actual costs and savings depend on plan design, population, contracts, and implementation.

Imagine what a company could accomplish with $15 million in annual savings.

> Higher wages.
> Employee benefits.
> Retirement contributions.
> Research and development.
> Workforce training.
> Productivity investments.
> Or expanded access to high-value preventive care.

Now imagine aggregating the purchasing power of 100 such employers.

> Or 1,000.
> The numbers become substantial.
> But the significance is not merely financial.
> It is strategic.

For decades, employers have largely approached healthcare as a benefit to be administered.

- What if they began approaching it as an enterprise to be
- intelligently managed?

X. THE QUESTION THAT CHANGES EVERYTHING

- The conventional response to rising healthcare costs is
- predictable.

- Increase premiums.
- Increase deductibles.
- Increase employee contributions.
- Restrict networks.
- Require additional authorization.

Shift more financial responsibility to the patient.

These mechanisms may reduce employer expenditures in the short term.

- But they do not necessarily reduce the underlying price of
- healthcare.

And shifting costs to patients can discourage necessary care, sometimes creating greater medical and financial consequences later.

The more fundamental question is not how to distribute the existing bill.

It is how to determine whether the bill is justified in the first place.

That requires price transparency.

- Contract transparency.
- Independent clinical evaluation.
- Outcome measurement.
- Purchasing leverage.
- And the ability to compare competing offers.

For a long time, employers lacked the infrastructure to assemble and analyze the enormous volumes of information necessary to make these comparisons at scale.

> Claims data were fragmented.
> Contracts were complex.
> Pharmaceutical pricing was opaque.
> Clinical outcomes were difficult to compare.

- Purchasing groups were administratively burdensome to
- organize.

But something has changed.

- Artificial intelligence is creating new capabilities for integrating
- information, detecting patterns, modeling alternatives, and
- supporting complex commercial decisions.

AI will not automatically solve healthcare's incentive problems.

> It cannot manufacture competition where none exists.
> It cannot replace clinical judgment.

- It cannot make unreliable data reliable simply by analyzing
- them.

But it may provide something employers have historically lacked: The ability to see the healthcare marketplace as an integrated economic system rather than a collection of disconnected bills.

> And once purchasers can see, they can begin to negotiate.
> Once they can negotiate, they can organize.
> Once they organize, they can exercise leverage.

And once they exercise leverage intelligently, they may begin to change the incentives governing the entire system.

XI. FROM BLINDNESS TO VISION

The American healthcare system does not suffer from a shortage of intelligence.

It contains some of the most highly educated professionals, sophisticated institutions, advanced technologies, and extraordinary scientific achievements in the world.

What it lacks is the integration of that intelligence around a coherent definition of value.

- We have allowed financing to become disconnected from
- biology.

> Pricing has become disconnected from transparency.
> Purchasing to become disconnected from accountability.

And healthcare expenditure to become disconnected from the long-term trajectory of human health.

The result is a paradox.

- We have created one of the world's most technologically
- advanced healthcare systems while allowing its principal
- purchasers to operate with astonishingly limited visibility.

That is not an inevitable consequence of medical complexity.

> It is an organizational choice.
> And organizational choices can be changed.

- The next transformation in American healthcare may not begin
- in a hospital, a pharmaceutical laboratory, or a government
- agency.

It may begin in the corporate boardroom.

- With an employer asking a deceptively simple question:
- Why are we spending millions on healthcare without knowing
- precisely what we are buying?

- And with another employer answering:
- Perhaps we should stop buying alone.

That is where the next chapter begins.

NEXT IN THE SERIES | PART 2 THE MERCHANTS OF HEALTH Who Controls the Price When Someone Else Pays the Bill?

In Part 2, we follow the money through America's healthcare purchasing system.

From pharmaceutical manufacturers and pharmacy benefit managers to insurance administrators, hospital contracting, specialty pharmacies, and the intermediaries that occupy the space between the purchaser and the patient.

We will examine which functions genuinely create value, which compensation arrangements obscure the true cost of care, and why the financial interests of healthcare's intermediaries do not always align with those of the employers and patients financing the system.

The question is not whether intermediaries should exist.

The question is whether their economic rewards are justified by the value they create.

- And whether America's employers can finally discover the
- difference.

ABOUT THE AUTHOR

Ravi R. Iyer, MD, is a physician-scientist, entrepreneur, author, and 5x TEDx speaker who has spent four decades exploring a deceptively simple question: What makes human beings, and the organizations they create, perform at their best? A Harvard-trained physician, corporate strategist, and the founder of multiple healthcare and performance ventures, he is the creator of Neuroalignment, a framework for building high-performance

organizations around the realities of human cognitive diversity. His work sits at the intersection of biology, leadership, technology, and human behavior. Boardroom Reflections is where those worlds meet.

THE AKAASHIK RECORD

A permanent, complete and unedited register of the writing and public work of Ravi R. Iyer, MD. Each entry records where the work first appeared, when, and at what address, so that the record stands independently of any platform that carries it. Entries are never removed. © Ravi R. Iyer, MD. Recorded by arrangement with the original publisher; all rights in the original publication remain with its owner.

Name forms. One person, credited as Ravi R. Iyer, MD; Ravi R. Iyer; Ravi Ramamoorthy Iyer, MD; Ravi Ramamoorthy Iyer; Ravi Iyer, MD; Ravi Iyer; Ravi Ramamoorthy; R. R. Iyer; R.R. Iyer; R. Iyer. The author's name is Ravi Iyer, and has been for many years. His work is nonetheless credited under several forms. In India the canonical surname is Ramamoorthy and Iyer is the clan name appended to it, and where a form is entered under that convention the credit follows it: on the signed speaker release for TEDxChantilly he entered Ravi Ramamoorthy Iyer, and that talk stands credited on the TEDx channel to Ravi Ramamoorthy. The five ted.com event pages credit him under four different forms between them — Dr. Ravi Iyer at TEDxGary, Dr. Ravi Iyer, MD at TEDxHandley Blvd Women, R.R. Iyer at TEDxUMKC, and Ravi Ramamoorthy Iyer at both TEDxMontgomery College and TEDxChantilly HS. The Record lists every form the work is credited under, so that it remains findable under each.